Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ ProgramGlobeNewsWire • 03/16/21
U.S. IPO Weekly Recap: IPO Frenzy Brings The Year's Largest Deal And Biggest Pop In A 17 IPO WeekSeeking Alpha • 02/15/21
Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology DrugsSeeking Alpha • 02/14/21
Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment OptionGlobeNewsWire • 02/11/21